OATP1B1-MEDIATED HEPATIC UPTAKE OF SN-38, AN ACTIVE METABOLITE OF IRINOTECAN, AND ITS INHIBITION BY UREMIC TOXINS IN HUMANS

被引：0
|
作者：
Fujita, K. [1 ]
Sugiura, T. [2 ]
Okumura, H. [2 ]
Umeda, S. [2 ]
Nakamichi, N. [2 ]
Sasaki, Y. [1 ]
Kato, Y. [2 ]
机构：
[1] Saitama Med Univ, Hidaka, Japan
[2] Kanazawa Univ, Kanazawa, Ishikawa, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S32 / S32
页数：1
相关论文
共 50 条
  • [31] Effects of SN-38, an active metabolite of irinotecan on p53 mediated apoptosis in human hepatocellular carcinoma cells
    Takeba, Yuko
    Kumai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 63 - 63
  • [32] Dissecting the relative contribution of OATP1B1-mediated uptake of xenobiotics into human hepatocytes using siRNA
    Williamson, B.
    Soars, A. C.
    Owen, A.
    White, P.
    Riley, R. J.
    Soars, M. G.
    XENOBIOTICA, 2013, 43 (10) : 920 - 931
  • [33] Effects of Oral Administration of S-1 on the Pharmacokinetics of SN-38, Irinotecan Active Metabolite, in Patients With Advanced Colorectal Cancer
    Yokoo, Koji
    Hamada, Akinobu
    Tazoe, Kensuke
    Sasaki, Yutaka
    Saito, Hideyuki
    THERAPEUTIC DRUG MONITORING, 2009, 31 (03) : 400 - 403
  • [34] Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1
    Nakagomi-Hagihara, R.
    Nakai, D.
    Tokui, T.
    Abe, T.
    Ikeda, T.
    XENOBIOTICA, 2007, 37 (05) : 474 - 486
  • [35] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Zhang, Ziqiang
    Yao, Jing
    Wu, Xiaotao
    Zou, Jianjun
    Zhu, Jiabi
    CHROMATOGRAPHIA, 2009, 70 (3-4) : 399 - 405
  • [36] A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients
    Denic, Kristina Zoran
    Neuhoff, Sibylle
    Reid, Joel
    Kudget, Rachel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [37] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Ziqiang Zhang
    Jing Yao
    Xiaotao Wu
    Jianjun Zou
    Jiabi Zhu
    Chromatographia, 2009, 70 : 399 - 405
  • [38] Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives
    Mullangi, Ramesh
    Ahlawat, Preeti
    Srinivas, Nuggehally R.
    BIOMEDICAL CHROMATOGRAPHY, 2010, 24 (01) : 104 - 123
  • [39] EFFECT OF BEVACIZUMAB ON P-GLYCOPROTEIN ACTIVITY AND ON THE PHARMACOKINETICS OF IRINOTECAN AND ITS MAIN ACTIVE METABOLITE (SN-38) IN VIVO
    Alili, Jean-Meidi
    Noel-Hudson, Marie-Sophie
    Chu, Celine
    Abbara, Chadi
    Farinotti, Robert
    Bonhomme-Faivre, Laurence
    ANNALS OF ONCOLOGY, 2012, 23 : 81 - 81
  • [40] Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan.
    Liu, W
    Innocenti, F
    Chen, PX
    Desai, A
    Grimsley, C
    Di Rienzo, A
    Das, S
    Ratain, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 148S - 148S
12345